Publications dans lesquelles il/elle collabore avec Carlos Mario Cárceles Rodríguez (55)

2023

  1. Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactiae pathogens in goats

    Research in Veterinary Science, Vol. 159, pp. 1-10

2021

  1. An in vivo pharmacokinetic study of metformin microparticles as an oral sustained release formulation in rabbits

    BMC Veterinary Research, Vol. 17, Núm. 1

  2. Pk/pd analysis of marbofloxacin by monte carlo simulation against mycoplasma agalactiae in plasma and milk of lactating goats after iv, sc and sc-long acting formulations administration

    Animals, Vol. 11, Núm. 4

2019

  1. Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration

    Journal of Equine Veterinary Science, Vol. 72, pp. 84-88

2018

  1. Pharmacokinetics of praziquantel and pyrantel pamoate combination following oral administration in cats

    Journal of Feline Medicine and Surgery, Vol. 20, Núm. 10, pp. 900-904

2017

  1. Susceptibility and PK/PD relationships of Staphylococcus aureus strains isolated from the milk of sheep and goats with clinical mastitis to five veterinary fluoroquinolones

    Veterinary Record, Vol. 180, Núm. 15

2016

  1. Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats

    BMC Veterinary Research, Vol. 12, Núm. 1

  2. Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use

    Journal of Oncology Pharmacy Practice, Vol. 22, Núm. 5, pp. 659-665

2015

  1. Evaluación de la estabilidad de mezclas estandarizadas triple intratecales de metrotexato sódico, citarabina e hidrocortisona fosfato sódico.

    60 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria

2013

  1. Pharmacokinetics of marbofloxacin in rabbit after intravenous, intramuscular, and subcutaneous administration

    Research in Veterinary Science, Vol. 94, Núm. 3, pp. 698-700

2012

  1. Short Communication: Fluoroquinolone susceptibility of Staphylococcus aureus strains isolated from commercial rabbit farms in Spain

    Veterinary Record, Vol. 170, Núm. 20

2011

  1. Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats

    Veterinary Journal, Vol. 188, Núm. 1, pp. 92-95

2010

  1. Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats

    Journal of Dairy Science, Vol. 93, Núm. 7, pp. 3056-3064

  2. Short communication: Fluoroquinolone susceptibility of Staphylococcus aureus strains isolated from caprine clinical mastitis in southeast Spain

    Journal of Dairy Science, Vol. 93, Núm. 11, pp. 5243-5245

2009

  1. Atlas de plantas medicinales y tóxicas

    Departamento de Farmacología, Toxicología y Medicina Legal y Forense, Universidad de Córdoba

  2. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep

    Veterinary Journal, Vol. 180, Núm. 3, pp. 343-347

  3. Pharmacokinetics and milk penetration of difloxacin after subcutaneous administration as a long-acting poloxamer 407 gel formulation to lactating goats

    XXXI Congreso de la Sociedad Española de Farmacología

  4. Pharmacokinetics of difloxacin after intravenous and subcutaneous administration, and as a long-acting poloxamer 407 gel formulation with carboxy-methylcellulose for subcutaneous administration to goats

    XXXI Congreso de la Sociedad Española de Farmacología

2008

  1. Disposition kinetics and pharmacokinetics-pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits

    Research in Veterinary Science, Vol. 84, Núm. 1, pp. 90-94

  2. Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration

    Journal of Veterinary Pharmacology and Therapeutics, Vol. 31, Núm. 1, pp. 77-82